恒常的で直接的なヒス・バンドル・ペース:正常なヒス・パーキンジェ活性化の患者における心臓ペースの新たなアプローチ
P Deshmukh1, D A Casavant, M Romanyshyn
1Cardiology Division, Robert Packer Hospital, Sayre, Penn, and Medtronic, Inc, Minneapolis, MN, USA.
Circulation
|March 1, 2000
まとめ
恒常的なHis-bundle pacing (DHBP) は,慢性心房細動および拡張性心筋症候群の特定の患者で実現可能である. この革新的なペースメソッドは,心臓の機能を改善し,心室の寸法を小さくし,従来のペースメソッドの代替手段として有望です.
科学分野:
- 心臓病学 心臓病学
- 電気生理学 電気生理学
- 医療機器 医療機器について
背景:
- ダイレクト・ヒス・バンドル・ペース (DHBP) は,アピカル・ペースと比較して同期した心室脱極化と改善された心機能を提供します.
- これまでのヒトでの恒久的なDHBPの試みは失敗し,臨床応用を制限しました.
研究 の 目的:
- 慢性心房細動および拡張性心筋症候群の患者において,恒常的な直接ヒースバンドルペース (DHBP) の実現可能性と結果を評価する.
主な方法:
- 慢性心房細動および拡張性心筋症の18人の患者を,電気生理学カテーテルを使用して永久的なDHBPのためにスクリーニングしました.
- 信頼性の高いHisバンドル刺激を受けた14人の患者のうち12人に恒久的なDHBPを成功裏に達成しました.
- 急速な心室応答を有する患者に放射性アブレーションを行い,単一室のペースレスポンシブペースメーカーを埋め込みました.
主要な成果:
- 恒久的なDHBPは12人の患者に成功裏に埋め込まれ,急性ペースの値2.4+/-1.0Vを示しました.
- 心臓機能の有意な改善が観察され,左心室の寸法が縮小し,エジェクション分子が増加しました.
- 2人の患者は8ヶ月と36ヶ月で死亡を経験し,ペースの手順とは無関係でした.
結論:
- 永続的なDHBPは,慢性心房細動および拡張性心筋症候群の選択された患者にとって実現可能で効果的なペース戦略です.
- DHBPは,左心室の大きさを大幅に減らし,心臓の全般的な機能を向上させます.
- このテクニックは,心臓のペースを調整する技術の潜在的進歩であり,血動力学的な利点が向上しています.
関連する概念動画
Pulse rhythm
1.7K
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
1.7K
Electrophysiology of Normal Cardiac Rhythm
7.8K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
7.8K
Conduction System of the Heart
13.8K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
13.8K
Dysrhythmias IV: Characteristics of Bradyarrhythmias
788
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
788
Dysrhythmias VI: Management of Dysrhythmias
599
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
599
Cardiomyopathy III: Hypertrophic Cardiomyopathy
812
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812


